Financial Analysis: Black Titan (NASDAQ:BTTC) versus Unisys (NYSE:UIS)

Unisys (NYSE:UIS) and Black Titan (NASDAQ:BTTC) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Volatility and Risk

Unisys has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Black Titan has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Unisys and Black Titan, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unisys	1	1	2	0	2.25
Black Titan	1	0	0	0	1.00

Unisys presently has a consensus target price of $5.00, suggesting a potential upside of 104.08%. Given Unisys’ stronger consensus rating and higher possible upside, research analysts clearly believe Unisys is more favorable than Black Titan.

Profitability

This table compares Unisys and Black Titan’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unisys	-21.65%	-14.09%	2.41%
Black Titan	N/A	N/A	N/A

Earnings and Valuation

This table compares Unisys and Black Titan”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unisys	$1.95 billion	0.09	-$339.80 million	($5.89)	-0.42
Black Titan	$180,000.00	47.56	-$4.71 million	($2.95)	-0.27

Black Titan has lower revenue, but higher earnings than Unisys. Unisys is trading at a lower price-to-earnings ratio than Black Titan, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.9% of Unisys shares are owned by institutional investors. 11.6% of Unisys shares are owned by company insiders. Comparatively, 0.7% of Black Titan shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Unisys beats Black Titan on 8 of the 14 factors compared between the two stocks.

About Unisys

Unisys Corporation, together with its subsidiaries, operates as an information technology solutions company in the United States and internationally. It operates in three segments: Digital Workplace Solutions (DWS); Cloud, Applications & Infrastructure Solutions (CA&I); and Enterprise Computing Solutions. The DWS segment provides advice and execution related to modern workplace solutions, such as communication and collaboration, intelligent workplace services, unified experience management, and modern device management; and traditional workplace solutions, including traditional service desk, device management and field services. The CA&I segment offers cloud management, hybrid infrastructure, modern applications, data and artificial intelligence, and cyber security; and design, implementation, monitoring, automation, and management of dedicated on-premises or hosted infrastructure. The Enterprise Computing Solutions segment provides license and support solutions; specialized services, next-generation computing, and industry solutions; and other solutions that provides various micro-market and business process solutions. The company also offers enterprise software and technology products, including Unisys InteliServe, PowerSuite, Unisys Logistics Optimization, CloudForte, ClearPath Forward, and Unisys Stealth. It serves its products in the travel and transportation, financial services, and healthcare industries. Unisys Corporation was founded in 1873 and is based in Blue Bell, Pennsylvania.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.